HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer

Mondal S, Roy D, Camacho-Pereira J, Khurana A, Chini E, Yang L, Baddour J, Stilles K, Padmabandu S, Leung S, Kalloger S, et al. (2015)
ONCOTARGET 6(32): 33705-33719.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ; ;
Alle
Abstract / Bemerkung
Warburg effect has emerged as a potential hallmark of many cancers. However, the molecular mechanisms that led to this metabolic state of aerobic glycolysis, particularly in ovarian cancer (OVCA) have not been completely elucidated. HSulf-1 predominantly functions by limiting the bioavailability of heparan binding growth factors and hence their downstream signaling. Here we report that HSulf-1, a known putative tumor suppressor, is a negative regulator of glycolysis. Silencing of HSulf-1 expression in OV202 cell line increased glucose uptake and lactate production by upregulating glycolytic genes such as Glut1, HKII, LDHA, as well as metabolites. Conversely, HSulf-1 overexpression in TOV21G cells resulted in the down regulation of glycolytic enzymes and reduced glycolytic phenotype, supporting the role of HSulf-1 loss in enhanced aerobic glycolysis. HSulf-1 deficiency mediated glycolytic enhancement also resulted in increased inhibitory phosphorylation of pyruvate dehydrogenase (PDH) thus blocking the entry of glucose flux into TCA cycle. Consistent with this, metabolomic and isotope tracer analysis showed reduced glucose flux into TCA cycle. Moreover, HSulf-1 loss is associated with lower oxygen consumption rate (OCR) and impaired mitochondrial function. Mechanistically, lack of HSulf-1 promotes c-Myc induction through HB-EGF-mediated p-ERK activation. Pharmacological inhibition of c-Myc reduced HB-EGF induced glycolytic enzymes implicating a major role of c-Myc in loss of HSulf-1 mediated altered glycolytic pathway in OVCA. Similarly, PG545 treatment, an agent that binds to heparan binding growth factors and sequesters growth factors away from their ligand also blocked HB-EGF signaling and reduced glucose uptake in vivo in HSulf-1 deficient cells.
Erscheinungsjahr
Zeitschriftentitel
ONCOTARGET
Band
6
Zeitschriftennummer
32
Seite
33705-33719
ISSN
PUB-ID

Zitieren

Mondal S, Roy D, Camacho-Pereira J, et al. HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. ONCOTARGET. 2015;6(32):33705-33719.
Mondal, S., Roy, D., Camacho-Pereira, J., Khurana, A., Chini, E., Yang, L., Baddour, J., et al. (2015). HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. ONCOTARGET, 6(32), 33705-33719.
Mondal, S., Roy, D., Camacho-Pereira, J., Khurana, A., Chini, E., Yang, L., Baddour, J., Stilles, K., Padmabandu, S., Leung, S., et al. (2015). HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. ONCOTARGET 6, 33705-33719.
Mondal, S., et al., 2015. HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. ONCOTARGET, 6(32), p 33705-33719.
S. Mondal, et al., “HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer”, ONCOTARGET, vol. 6, 2015, pp. 33705-33719.
Mondal, S., Roy, D., Camacho-Pereira, J., Khurana, A., Chini, E., Yang, L., Baddour, J., Stilles, K., Padmabandu, S., Leung, S., Kalloger, S., Gilks, B., Lowe, V., Dierks, T., Hammond, E., Dredge, K., Nagrath, D., Shridhar, V.: HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. ONCOTARGET. 6, 33705-33719 (2015).
Mondal, Susmita, Roy, Debarshi, Camacho-Pereira, Juliana, Khurana, Ashwani, Chini, Eduardo, Yang, Lifeng, Baddour, Joelle, Stilles, Katherine, Padmabandu, Seth, Leung, Sam, Kalloger, Steve, Gilks, Blake, Lowe, Val, Dierks, Thomas, Hammond, Edward, Dredge, Keith, Nagrath, Deepak, and Shridhar, Viji. “HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer”. ONCOTARGET 6.32 (2015): 33705-33719.

7 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M., Br J Cancer (), 2018
PMID: 29531325
Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT, Wei WJ, Qiu ZL, Song HJ, Zhang XY, Sun ZK, Luo QY., J Mol Endocrinol 58(1), 2017
PMID: 27920093
Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin.
Mahmoud SA, Ibrahim MM, Musa AH, Huang Y, Zhang J, Wang J, Wei Y, Wang L, Zhou S, Xin B, Xuan W, Tang J., J Cell Commun Signal (), 2017
PMID: 29275459
The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.
Yu L, Chen X, Wang L, Chen S., Oncotarget 7(25), 2016
PMID: 26918353
Disruption of the EZH2/miRNA/β-catenin signaling suppresses aerobic glycolysis in glioma.
Wang Y, Wang M, Wei W, Han D, Chen X, Hu Q, Yu T, Liu N, You Y, Zhang J., Oncotarget 7(31), 2016
PMID: 27385092
Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B, Yang Y., Exp Hematol 44(11), 2016
PMID: 27576132

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 26378042
PubMed | Europe PMC

Suchen in

Google Scholar